

Advisory Board on the Registration of Homeopathic Products

Herbal Medicines Advisory Committee

Annual Report 2019

Medicines & Healthcare products Regulatory Agency

**Advisory Board on the
Registration of Homeopathic
Products**

**Herbal Medicines Advisory
Committee**

Annual Reports 2019

LIST OF CONTENTS

Foreword	5
Report on the Advisory Board on the Registration of Homeopathic Products	6
Report of the Herbal Medicines Advisory Committee	13
Code of Practice for Chairmen and Members of the Commission on Human Medicines, Certain Committees and Expert Advisory Groups	21
Members' Interests:	
Advisory Board on the Registration of Homeopathic Products	31
Herbal Medicines Advisory Committee	32

FOREWORD BY SIR MICHAEL RAWLINS, CHAIRMAN OF THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

I am pleased to present the Annual Reports of the Advisory Board on the Regulation of Homeopathic Products and the Herbal Medicines Advisory Committee, along with a record of Members' interests in the pharmaceutical industry and code of practice.

Importantly, the work of our Expert committees continues to meet the highest standards. I would like to thank the Chair and Members whose professional expertise, commitment and hard work, play a vital role to ensure the medicines we take continue to be safe.

Sir Michael Rawlins
Chairman of the MHRA

ADVISORY BOARD ON THE REGISTRATION OF HOMEOPATHIC PRODUCTS ANNUAL REPORT 2019

INTRODUCTION

1. The Advisory Board on the Registration of Homeopathic Products ('the Board') was established in 1994 by the Medicines (Advisory Board on the Registration of Homeopathic Products) Order 1994 (S.I. 1994/102) which was revoked and replaced by the Medicines (Advisory Board on the Registration of Homeopathic Products) Order 1995 (S.I. 1995/309), as amended by the Medicines (Advisory Board on the Registration of Homeopathic Products) Order 2006 (S.I. 2006/2386), pursuant to the powers contained in section 4 of the Medicines Act 1968 as amended by the Part 1 of Schedule 11 to the Medicines Regulations 2012.
2. The Board changed on the 1st November 2012 from being an Advisory Non-Department Public Body (ANDPB) to an MHRA Expert Committee.

Its terms of reference are:

- a) to give advice on safety and quality in relation to any homeopathic medicinal product for human use, in respect of which a certificate of registration has been granted or applied for.
- b) to give advice on safety, quality and indications for use within the UK homeopathic tradition in relation to any homeopathic medicinal product for human use,
 - i) in respect of which a marketing authorisation has been granted or has been applied for, or
 - ii) in respect of which a licence of right has been granted.

MEMBERSHIP

3. A list of the Board's current membership is at **Appendix I**.

SECRETARIAT

4. The Secretariat is based at the Medicines and Healthcare products Regulatory Agency. A list of the secretariat is at **Appendix II**.

MEETINGS

5. There were two meetings in 2019. Meetings were held at the Medicines and Healthcare Products Regulatory Agency, 10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom.

6. Summary minutes of the meetings can be found on the MHRA website <https://www.gov.uk/government/groups/advisory-board-on-the-registration-of-homeopathic-products>.

COSTS

7. Members are entitled to claim an attendance fee of £325 per day (Chairman's fee £500). Travel and subsistence is also payable within Department of Health guidelines.

SAFETY ISSUES

Reporting of suspected adverse drug reactions


8. Suspected adverse reactions to medicinal products including homeopathic medicines are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) on a voluntary basis by healthcare professionals and patients through the Yellow Card Scheme.
9. Information collected through the scheme is an important means of monitoring safety, acting as an early warning system for the identification of previously unrecognised adverse reactions and increasing knowledge of known adverse reactions.

Table 1: Breakdown of the number of reports of suspected adverse reactions

Year received	Total number of reports received	Number of serious reports received	Number of reports received from patients
2006	0	0	0
2007	2	2	0
2008	0	0	0
2009	2	2	1
2010	2	2	0
2011	3	1	1
2012	1	1	0
2013	0	0	0
2014	1	0	0
2015	0	0	0
2016	2	1	1
2017	3	3	1
2018	1	0	0
2019*	2	1	0

* Received between 1 January 2019 and 28 November 2019

Figure 1: Breakdown of reports received between 2006 and 2019



*2019 covers the period 1 January to 28 November 2019.

10. During 2019 two cases of possible adverse reactions to homeopathic products were received through the Yellow Card Scheme and reviewed by the Board. The Board agreed that no new safety signals had been identified and that no regulatory action was required.
11. The MHRA will continue to monitor any adverse reactions received.
12. The MHRA are continuing to actively seek ways to improve the level of reporting for medicines, including homeopathic medicines. The Board is grateful for the co-operation of those healthcare professionals and patients who submit reports of suspected adverse reactions and encourages the reporting of all suspected reactions to homeopathic medicines.

SUMMARY

13. In 2019, the Board advised on one new application for a homeopathic national rules authorisation submitted under the National Rules Scheme.
14. The Board also received updates on European issues.
15. Tables showing the number of applications made for registration certificates and homeopathic marketing authorisations and the number of those referred to the Board for advice since it was established is at **Appendix III**.

MEMBERSHIP OF THE ADVISORY BOARD ON THE REGISTRATION
OF HOMEOPATHIC PRODUCTS

Chair

Professor Angus Mackay OBE MA PhD (Cantab) MB ChB BSc
(Pharmacol) FRCP (Edin) FRCPsych TPsych
Professor of Psychological Medicine, University of Glasgow

Members

Dr Robert C G Bracchi BSc MB BCh MD FRCGP
Retired General Practitioner

Mrs Patricia Donnachie RN OHNP MF (Hom) FF (Hom)
Service Support Manager Renal and Integrative Care, Advance Nurse
Practitioner Integrative Care. NHS Centre for Integrative Care, Gartnavel
Campus, Glasgow

Ms Susan Hunneyball¹ BSc (Hons)
Lay Member

Professor George B Lockwood² BPharm (Hons) PhD MRPharmS
Professor of Pharmaceutical Sciences, Division of Pharmacy & Optometry
School of Health Sciences, University of Manchester

Dr Frank Mulder
General Practitioner, Helios Medical Centre, Bristol

Dr Gary J Smyth MB ChB DGM DMH DRCOG DFSRH MRCGP FFHom
General Practitioner and Homeopathic Physician, Belfast, Northern Ireland

Professor Susan Barker³ B.Pharm. (Hons), Ph.D., PGCHET
Head of the Medway School of Pharmacy, Medway School of Pharmacy,
Universities of Greenwich and Kent at Medway. Kent

Dr Jennifer Lenhart⁴ BSc MedSci., MB,ChB., MFHom, MA.
Associate Specialist Homeopathic Physician, The Royal London Hospital
for Integrated Medicine, UCLH NHS Trust, London

Ms Sarah Mawhinney⁵ Bsc (Hons), MPSNI, FPS, DF Hom(Pharm)
Community Pharmacist Northern Ireland

¹ Reappointed 19/10/2019

² Reappointed 19/10/2019

³ Appointed 14/01/2019

⁴ Appointed 14/01/2019

⁵ Appointed 14/01/2019

**MEMBERS OF THE ADVISORY BOARD'S ADMINISTRATIVE
SECRETARIAT**

Dr Elizabeth Griffiths
Principal Assessor

Dr Swati Bhat
Medical Assessor

Mr Jasvinder Sumal
Pharmaceutical Assessor

Ms Lorraine Gear
Unit Manager

Ms Pauline Edwards
Secretary

Homeopathic Registrations					
Year	Applications Received	Applications Referred to ABRHP			Total
		Provisional Refusal	Grant Advised	Conditional Grant	
1994	25	0	0	0	0
1995	24	10	0	3	13
1996	54	2	0	0	2
1997	88	2	0	1	3
1998	70	0	0	0	0
1999	73	3	0	3	6
2000	9	0	0	0	0
2001	13	0	0	0	0
2002	11	0	0	0	0
2003	0	0	2	0	2
2004	30	0	0	0	0
2005	13	0	0	0	0
2006	4	1	0	1	2
2007	1	0	0	1	1
2008	2	0	0	2	2
2009	5	0	1	2	3
2010	10	1	1	7	9
2011	17	0	2	10	12
2012	8	0	0	8	8
2013	4	0	0	11	11
2014	3	1	0	3	4
2015	0	0	0	2	2*
2016	3	0	0	0	0
2017	0	0	0	1	1
2018	0	0	0	1	1
2019	0	0	0	0	0
Total	467	20	6	56	82

*Received pre-2015

Homeopathic Marketing Authorisations					
Year	Applications Received	Applications Referred to ABRHP			Total
		Provisional Refusal	Grant advised	Conditional Grant	
2007	1	0	0	1	1
2008	2	0	0	2	2
2009	5	0	1	2	3
2010	10	1	1	7	9
2011	17	0	2	10	12
2012	8	0	0	8	8
2013	4	0	0	11	11
2014	3	1	0	3	4

2015	0	0	0	2	2*
2016	3	0	0	0	0
2017	0	0	0	1	1
2018	0	0	0	0	0
2019	1	0	0	1	1
Total	54	2	4	48	54

*Received pre-2015

HERBAL MEDICINES ADVISORY COMMITTEE

ANNUAL REPORT 2019

INTRODUCTION/BACKGROUND

1. The Herbal Medicines Advisory Committee (“the Committee”) was established under the powers contained in section 4 of the Medicines Act 1968 as amended by the Part 1 of Schedule 11 to the Medicines Regulations 2012, and the Committee was formally created on 30 October 2005. The functions of the Committee are set out in the Herbal Medicines Advisory Committee Order 2005.
2. The Committee changed on the 1st November 2012 from being an Advisory Non-Departmental Public Body (ANDPB) to an MHRA Expert Committee. Its terms of reference are stated below.
3. The Herbal Medicines Advisory Committee advises on the safety, quality and efficacy, in relation to human use, of:
 - 3.1 herbal medicinal products eligible for registration under the simplified traditional use registration procedure established under European Directive 2004/24/EC and;
 - 3.2 unlicensed herbal medicinal products (unless it is subject to an application for a marketing authorisation, product licence or a homeopathic certificate of registration).
4. The Committee may also advise on the safety, quality and efficacy, in relation to human use, of herbal medicinal products which have a marketing authorisation, product licence or certificate of registration, or which are the subject of an application for such authorisation, licence or certificate, if Health Ministers or the licensing authority request such advice, or provide the Committee with information relating to that product.
5. The primary role of the Committee will be issues relating to safety and quality, since there is not a requirement for efficacy to be separately demonstrated in relation to registered traditional herbal medicines or unlicensed products sold under section 241 of the Human Medicines Regulations. However, efficacy is still relevant - under the traditional herbal registration scheme, the pharmacological effects or efficacy of the medicinal product must be plausible on the basis of long-standing use and experience.

CHAIRMAN/MEMBERS

6. A list of the Committee’s current membership is at **Appendix I**.

SECRETARIAT

7. The Secretariat is based at the Medicines and Healthcare products Regulatory Agency. A list of the secretariat is at **Appendix II**.

MEETINGS

8. There were 3 meetings in 2019. Meetings were held at the Medicines and Healthcare Products Regulatory Agency, 10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom.
9. Summary minutes of the meetings of the Committee can be found on the MHRA website <https://www.gov.uk/government/groups/herbal-medicines-advisory-committee>.

COSTS

10. Members are entitled to claim an attendance fee of £325 per day (Chairman's fee £500). Travel and subsistence is also payable within Department of Health guidelines.

TRADITIONAL HERBAL REGISTRATIONS

11. During the year, four applications were approved; none were referred to HMAc. Table 1 lists the number of THR applications received.

Table 1: Number of Traditional Herbal Registrations

Year received	Number of applications received	Number of applications referred to HMAc	Number of applications approved
2006	14	2	1
2007	17	4	6
2008	20	2	18
2009	47	6	22
2010	88	4	36
2011	52	5	66
2012	47	2	43
2013	169	2	126
2014	6	3	8
2015	9	2	11
2016	3	2	4
2017	7	1	6
2018	10	1 (Variation)	7
2019	0	0	4

SAFETY ISSUES

Reporting of suspected adverse drug reactions


12. Suspected adverse reactions to medicinal products including herbal medicines are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) on a voluntary basis by healthcare professionals and patients through the Yellow Card Scheme. Reports are also submitted as a legal requirement by companies holding Marketing Authorisations or Traditional Herbal Registrations.
13. Information collected through the scheme is an important means of monitoring safety, acting as an early warning system for the identification of previously unrecognised adverse reactions and increasing knowledge of known adverse reactions.
14. At their meetings in 2019 the Committee reviewed details of adverse reactions received during the period 1 Jan to 30 November 2019. A total of 70 reports which were suspected to be associated with herbal medicinal products were reviewed. The number of reports received each year through the Yellow Card scheme provided in Table 2, excludes products which are considered to be foods, devices, cosmetics, homeopathic products, licensed medicines not considered to be herbal medicines and unlicensed products which contain non-herbal ingredients such as animal parts. This data is also presented in Figure 1 below.

Table 2: Breakdown of reports received of suspected adverse reactions

Year received	Total number of reports received	Number of serious reports received	Number of reports received from patients
2006	81	61	41
2007	52	42	16
2008	62	51	18
2009	59	54	20
2010	54	46	17
2011	57	48	24
2012	45	24	19
2013	68	44	34
2014	51	30	29
2015	95	54	69
2016	89	55	58
2017	103	52	75
2018	92	60	62
2019*	70	45	54


*1 January 2019 to 30 November 2019

Figure 1: Breakdown of reports received between 1 January 2006 and 30 November 2019



15. The Committee is grateful for the co-operation of those healthcare professionals and patients who submit reports of suspected adverse reactions and encourages the reporting of all suspected reactions to herbal medicines. A direct comparison of cumulative reporting rates for 2018 and 2019 is provided in Figure 2 below.

Figure 2: Cumulative number of reports received by month for 2018 and 2019



16. Healthcare professionals and patients are continuing to submit reports through the Yellow Card scheme about suspected adverse reactions involving a range of herbal medicines, with patients increasingly reporting problems directly via the Yellow Card scheme.
17. Patients (or their family members) submitted the largest proportion of Yellow Card reports received in 2019 (77% of the total). The majority of patient reports were submitted directly to the Yellow Card scheme (n=48) but some were received via the Traditional Herbal Registration Holders (n=6).
18. The proportion of serious reports received in 2019 for herbal medicines is approximately 65%, which is consistent with last year.
19. The MHRA are continuing to actively seek ways to improve the level of reporting for herbal medicines. It is recognised that the continued success of the Yellow Card Scheme depends on the willingness of healthcare professionals and patients to report suspected ADRs and that the Committee supports the ongoing activities of the MHRA to promote the scheme.

CONSIDERATION OF OTHER MATTERS

20. During the year, the Committee noted reports, European Union Herbal Monographs and Public Statements from the Herbal Medicinal Products Committee meetings.

MEMBERSHIP OF THE HERBAL MEDICINES ADVISORY COMMITTEE

Chair

Professor Philip A Routledge⁶ OBE MD FRCP FRCPE FBTS FRSB
FAcadMed FRCGP(Hon) FFPM(Hon) HonFBPhS
Professor of Clinical Pharmacology and Head of the Department of
Pharmacology, Therapeutics and Toxicology, Cardiff University and
Honorary Consultant Physician/Clinical Pharmacologist in Cardiff and Vale
University Health Board

Members

Dr Robert C G Bracchi⁷ BSc MB BCh MD FRCGP
Retired General Practitioner

Dr Paul D Bremner PhD BSc MBA SFHEA
Senior Lecturer, De Montfort University

Ms Alison M Denham⁸ MA FNIMH FHEA
Herbal Practitioner and Senior Lecturer in Herbal Medicine, University of
Central Lancashire, Preston

Dr Shantha B W Godagama⁹ DAMS MBAC MF (hom) MAcF FAMA
(UK)
Ayurvedic physician, Qualified Acupuncturist, Founder of Ayurvedic
Medical Association U.K., College of Ayurveda, Author of Hand Book of
Ayurveda, Director of the Ayurvedic Centre, Hale Clinic, London.

Professor Michael Heinrich MA MSc PhD
Professor and Head of Centre, UCL School of Pharmacy, University of
London

Dr Barbara A Pendry¹⁰ PhD BSc (Hons) PGCE MNIMH
Principal Lecturer, Herbal Practitioner and Programme Leader for Herbal
Medicine at the University of East London

Professor Raymond J Playford MB BS PhD FRCP FAcadMedSci
Professor of Medicine, University of Plymouth & visiting Consultant, St
George's University Hospitals NHS Foundation Trust

⁶ End of appointment 31/12/2019

⁷ End of appointment 31/12/2019

⁸ End of appointment 31/12/2019

⁹ End of appointment 31/12/2019

¹⁰ Reappointed 01/09/2019

Mrs Farrah Pradhan¹¹

Invited Reviews Manager Royal College of Obstetricians and Gynaecologists, London

Dr Deborah J Shaw¹² BSc (Hons) PhD

Independent Consultant on Herbal Safety and Pharmacovigilance

Dr David Tuthill MB BCh FRCPCH

Consultant Paediatrician, Children's Hospital for Wales, Cardiff

Professor Heather M Wallace PhD FRCPath FRSC FSB FBPharmacolS

FBTS European Registered Toxicologist

Professor of Biochemical Pharmacology and Toxicology, Division of Applied Medicine, University of Aberdeen

Dr Jidong Wu MB MSc PhD MATCM

Senior Lecturer and Programme Advisor in Traditional Chinese Medicine at Middlesex University

Dr Kaicun Zhao MB MSc PhD

Programme Leader, Traditional Chinese Medicine, Department of Mental Health, Social Work and Integrative Medicine, Middlesex University London

¹¹ End of appointment 12/02/2019

¹² End of appointment 31/12/2019

Members of the Committee's Administrative Secretariat

Dr Linda Anderson
Principal Assessor

Mrs Leigh Henderson
Safety

Ms Lorraine Gear
Unit Manager

Mrs Munise Guler
Secretary

CODE OF PRACTICE FOR CHAIRPERSONS AND MEMBERS OF THE COMMISSION ON HUMAN MEDICINES, CERTAIN COMMITTEES AND EXPERT ADVISORY GROUPS

INTRODUCTION

Purpose of the Code

- 1.1 This Code of Practice sets out the rules to be followed by chairpersons and members of advisory committees holding and declaring interests in the pharmaceutical industry. The Code of Practice also provides guidance on holding and declaring other relevant interests, and on how interests that have been declared will be managed. The Code applies to chairpersons and members of all the statutory committees and Expert Advisory Groups (EAGs) established to contribute advice to the Licensing Authority on the regulation of medicines available on the UK market. Separate rules apply to the British Pharmacopoeia Commission (BPC) because of their different role and remit.

Importance of impartiality

- 1.2 Ministers expect the advice they receive on matters relating to the regulation of medicines to be impartial. Ministers also expect to be able to seek such advice from a wide range of highly skilled professionals who are senior and well regarded in their respective fields. Many experts in the field of medicines have, or have had, connections with the pharmaceutical industry and other commercial organisations whose business may be considered relevant to their work on the advisory bodies but may have an impact on their impartiality. For example, the University department for which an individual is responsible may have received a research grant from industry, or the individual may have shareholdings from previous industry employment.
- 1.3 To reassure Ministers and the public that the advice on which decisions about medicines is based is impartial, it is important to have in place a robust policy governing the declaration and management of relevant interests. In the interests of transparency and accountability, this Code of Practice, the declarations made by the chairperson and members of the various committees, and the actions taken to manage potential conflicts of interest are made public. In addition, where an individual has declared in advance of a meeting an interest that would exclude him or her from the relevant discussions, this information will be used by the secretariat to ensure that, wherever possible, the relevant committee papers are not sent to that individual.

SCOPE

Committees and groups to which this Code applies

- 2.1 The Code of Practice applies to the chairperson and members of the following committees and groups:
 - Commission on Human Medicines (CHM)

- The following committees (“the Committees”):
 - Herbal Medicines Advisory Committee (HMAC);
 - The Advisory Board on the Registration of Homeopathic Products (ABRHP)
 - The Expert Advisory Groups (EAGs) established by the CHM and/or the Committees.
- 2.2 This Code of Practice does not apply to the British Pharmacopoeia Commission (BPC), which does not advise Ministers directly. A separate Code has been developed for the BPC to take account of their different role and remit.

DEFINITIONS

3.1 For the purposes of this Code of Practice, the following definitions apply:

Pharmaceutical Industry

3.2 “Pharmaceutical industry” means:

- Companies, partnerships or individuals who are involved with the manufacture, sale or supply of medicinal products, including herbal medicinal products and homeopathic products
- Trade associations representing companies involved with such products
- Companies, partnerships or individuals who are directly concerned with research, development or marketing of a medicinal product, including herbal medicinal products and homeopathic products which is being considered by the CHM or by one of the Committees or Expert Advisory Groups.

References to “the pharmaceutical industry” include cases involving a single company.

Immediate family

3.3 “Immediate family” means:

- Spouse or partner and members of the family living in the same household. Members of the family include dependent children, any adult children or other relative (such as parent) living in the same household.

INTERESTS WHICH NEED TO BE DECLARED

Summary of interests that need to be declared

- 4.1 It is the responsibility of each individual to identify and to declare all relevant interests. The following types of interest must be declared by the chairperson and members of all committees and groups:
- Their own financial interests in the pharmaceutical industry; (financial interests are either personal or non-personal, and either specific to the product being discussed, or non-specific)
 - Financial interests in the pharmaceutical industry held by members of their immediate family
 - Any other matter that could affect their impartiality, or that could reasonably be perceived as affecting their impartiality. Some examples of interests that are relevant in the context of this Code of Practice, not all associated with the pharmaceutical industry, are set out in section 4.7 below.

- 4.2 The following paragraphs describe in more detail the types of interests that must be declared. The procedures for handling interests that have been declared are described in Section 7.

Personal interests

- 4.3 A personal interest in the context of this Code, involves the payment, in any form, to an individual personally, by a pharmaceutical company whose business may be directly affected by the advice of the advisory body. At a meeting, personal interests must be declared as specific (that is, payment relates to a particular product under consideration), or as non-specific (that is, not related to the particular product under discussion). The following main examples of interests to be declared should not be regarded as a definitive list, and the Medicines and Healthcare products Regulatory Agency (MHRA) secretariat to each committee will advise if a chairperson or member is in any doubt.

Consultancies: any consultancy, directorship, position in or work for the pharmaceutical industry which attracts regular or occasional payments in cash or kind

Fee-paid work: any work commissioned by the pharmaceutical industry for which the individual is paid in cash or kind

Shareholdings: any shareholding in or other beneficial interest in the pharmaceutical industry. This does not include shareholdings through unit trusts or similar arrangements where the individual has no influence on financial management

Expenses/hospitality provided by a pharmaceutical company: special rules apply to attendance at conferences or similar events. These are covered in paragraphs 4.8 et seq. below

Unit trusts and similar: Assets over which the chairperson and members and/or their immediate family have no financial control (such as holdings in a wide share portfolio -Unit Trust or similar - where the Fund Manager has full discretion over the composition of the portfolio) do not need to be declared. However, funds held in a portfolio in which the chairperson and members and/or their immediate family have the ability to instruct the Fund Manager as to the composition of the fund must be declared.

Pension entitlement: Accrued pension rights from earlier employment in the pharmaceutical industry do not need to be declared.

Personal interests - special rules applicable to the CHM and the Committees

- 4.4 The chairperson and members of the CHM, HMAc and ABRHP serve on the committees that provide advice direct to the Licensing Authority. For this reason, they are not permitted to hold any current personal interests in the pharmaceutical industry. This policy also applies to the chairperson of the Chemistry, Pharmacy and Standards EAG, the Pharmacovigilance EAG and the Biologicals and Vaccines EAG by virtue of their membership of the CHM. The chairperson and members of the CHM and the chairperson and members of the HMAc and ABRHP, and the chairperson of the three EAGs specified are required to make a declaration on appointment that they are disposing /have disposed of any such current personal interests.

- 4.5 The chairperson and members of these committees have three months from the date of appointment to dispose of any current personal interests in the pharmaceutical industry. During this period, they are required to declare any relevant current personal interests at meetings and to exclude themselves from discussion on the relevant product(s) and abstain from any vote.

Non-personal interests

- 4.6 A non-personal interest in the context of this Code, involves payment that benefits a department for which an individual is responsible, but is not received by the member personally. As with personal interests, non-personal interests at a meeting must be specific or non-specific. The main examples that follow should not be regarded as a definitive list, and the advice of the committee secretariat provided by the MHRA should be sought if a chairperson or member is in any doubt.

Fellowships: the holding of a fellowship endowed by the pharmaceutical industry or any other relevant industry

Support by the pharmaceutical industry or any other relevant industry: any payment, other support or sponsorship by the pharmaceutical or other industry that does not convey any pecuniary or material benefit to the individual personally but that benefits his/her position or department

Grants from a company: for example, for the running of a unit or department for which an individual is responsible

Grants or fellowships to sponsor a post or staff member in the unit for which the individual is responsible: this does not include financial assistance given to individual students

Commissioning of research or other work or advice from staff who work in a unit for which the individual is responsible.

Other relevant interests

- 4.7 It is not only financial interests in the pharmaceutical industry that are relevant. A wide range of other matters may also be considered to be relevant, depending on the circumstances and matters under consideration by a committee on which an individual serve, and could include non-financial interests. There are no hard and fast rules concerning “other” interests that need to be declared. In considering whether an interest is relevant and therefore should be declared, the guiding principle must be whether the matter might reasonably be perceived as affecting a member’s impartiality. Some examples of matters that might fall under this heading are set out below. These are not exhaustive, and individuals should always seek advice from the MHRA Secretariat if they are in any doubt about whether or not a matter is relevant:

- An individual, or his department, has done research work relating to a particular product, or class of products. Although the research has not been funded by any particular pharmaceutical company, the research has taken a particular line e.g. in relation to the safety of the products, or their efficacy
- An individual has made public statements (either favourable or unfavourable) about a particular company, or product, or class of products or about a competitor’s product or class of product

- The relevant committee is considering whether a product should be reclassified e.g. from prescription only, to a pharmacy medicine, and the individual has a particular interest in the reclassification being made e.g. because he is a retail pharmacist and he will benefit financially
- An individual participates in, or is connected with, a charity or pressure group that would have an interest in the outcome of the advice being given
- An individual has a family member who suffers from an illness who would benefit from treatment if a product under discussion were to be authorised
- An individual has a family member who has suffered a severe reaction or other problem as a result of treatment with a product under discussion
- Matters relating to persons who are not immediately family members, but are closely connected with the committee expert e.g. adult child no longer living in the same household, or non-family member whose work or other interests are closely associated with the pharmaceutical industry and which could reasonably be perceived as affecting the individual's impartiality. An example might be where a committee is giving advice in relation to a product and a close family member or friend has had a major development responsibility for that product
- Interests in a company manufacturing the delivery system (e.g. syringes or other medical equipment) for a particular medicinal product

Attendance at conferences, scientific meetings and similar

- 4.8 Government recognises that it is usual for conferences, scientific meetings and other events associated with healthcare, medicines or related matters to receive some form of sponsorship either directly, or indirectly via a special fund, from the pharmaceutical industry. Government also recognises the importance of being able to receive advice from leading experts who are able to keep themselves up to date with developments at the cutting edge of science, and that this is mainly done through attendance at educational and scientific events and meetings. It is therefore essential to set out rules for attendance at these and similar events as questions may be legitimately raised as to whether participation in the event, or even mere attendance, will compromise their impartiality in any way. This is particularly important in respect of the chairperson and members of the CHM, HMAc and ABRHP (including the chairperson of the Chemistry, Pharmacy and Standards EAG, the Pharmacovigilance EAG and the Biologicals and Vaccines EAG) who, as set out above, are not permitted to hold personal interests in the pharmaceutical industry.
- 4.9 The nature of the events that fall within the scope of this Code of Practice and the industry sponsorship received can vary widely from, at one extreme, a conference sponsored by a single company to launch a product to, at the other extreme, a scientific meeting organised by a learned society that has received some financial support from a number of companies paid into a dedicated meeting fund. Between these extremes there are many variations in events and funding that may occur.
- 4.10 In order that the chairperson and members of CHM, HMAc, ABRHP and the three EAG chairperson specified in paragraph 4.8 above should be able to attend appropriate scientific events to keep their knowledge up to date, the MHRA has established a discretionary fund to meet the reasonable expenses (e.g. travel and accommodation costs) incurred in their attendance. The relevant MHRA committee secretariat will administer the fund, and chairperson and members wishing to claim the costs of attendance at such events must make an application

in good time to enable appropriate travel and other arrangements to be made. The fund will cover educational events that are relevant to maintaining the expertise of individuals serving on the CHM, HMAc, ABRHP and the three specified EAGs, where acceptance of financial support from industry (for example a single pharmaceutical company) would not be appropriate. Separate guidance on the allocation of resources from the fund has been developed for use by the MHRA secretariat.

- 4.11 In some cases, it will be permissible for members of CHM, HMAc, ABRHP or the EAG chairperson to attend events sponsored by the pharmaceutical industry (and accept the payment of their expenses) without recourse to the MHRA discretionary fund. For example, where a learned society holds an international conference that is sponsored by a number of different pharmaceutical companies, it will generally be acceptable for the member to accept such an invitation and to receive payment of expenses, although in such instances declaration of attendance and receipt of funding must be declared in the normal way.
- 4.12 If funding and/or expenses are paid specifically for an individual's attendance but nevertheless paid to his department rather than the individual himself, it will not normally be acceptable for the individual to attend.
- 4.13 Benefits of this nature paid to an immediate family member that also benefit the committee chairperson or member (e.g. a company pays his or her flight costs so that he or she can attend a conference with a family member) must be declared as the individual's own interest. However, there is no requirement to declare educational conferences and similar events attended by immediate family members.
- 4.14 If an individual attends an educational conference or similar, he or she should avoid participation in, for example, "satellite" meetings sponsored and arranged by specific companies or focusing on specific products where involvement in discussions might reasonably be perceived as affecting his or her impartiality. If in doubt, this must be raised with the MHRA Secretariat at the earliest possible opportunity, who will be able to provide further guidance.
- 4.15 The rules for holding personal interest in the pharmaceutical industry do not apply to the chairperson and members of EAGs, apart from the chairperson of the three EAGs described at paragraph 4.8 above, and for the reasons set out in paragraph 4.4 above. Therefore, these experts may attend meetings sponsored by the pharmaceutical industry and accept funding of expenses, but these must be declared.
- 4.16 Attendance at conferences, scientific meetings and other events relevant to this Code must be declared at the first meeting of the committee after the event has taken place. This declaration may affect an individual's participation in discussions over the subsequent months. The declarations will be published annually in the report of the work of the committees.
- 4.17 The situations described are not exhaustive and individuals should always seek advice from the MHRA Secretariat if they are in any doubt about whether or not they should attend, or whether, having attended, they need to declare attendance as an interest.

SPECIAL POSITION OF EXPERTS ATTENDING FOR THE DAY AND EXPERTS CALLED TO ADVISE THE COMMITTEES ON SPECIFIC ISSUES

- 5.1 Experts who are invited to attend committees for the day, for example if a regular member cannot be available or cannot participate in discussions because of his or her interests, are known as “Experts for the Day”. They are co-opted as full members of the committee for that day, may participate fully in all discussions and may vote. They are therefore required to make a full declaration of interests in the same way as is required of a full member of that committee. Experts called to advise a committee on particular issues may not hold interests in the issue under discussion.

DECLARATION OF INTERESTS

- 6.1 Chairpersons and members are required to make a full declaration of interests on appointment and annually. They must also inform the MHRA secretariat promptly of any changes or updates to the terms of their declaration during the year. This includes reporting promptly attendance at events described in paragraphs 4.8 – 4.17. If an individual is uncertain as to whether or not an interest should be declared, he or she must seek guidance from the MHRA secretariat. Chairpersons and members are also required to make further declarations of relevant interests at meetings when they will be advised as to the procedure that will apply.

Annual declaration

- 6.2 The annual declaration must include all the financial (personal and non-personal) interests in the pharmaceutical industry of the chairperson and members currently held or held in the last 12 months and financial interests in the pharmaceutical industry that they know of that are held by their immediate family. Members and chairpersons are also required to include in the annual declaration details of any other matter which could reasonably be regarded as affecting their impartiality.
- 6.3 The declaration of certain interests will not be restricted to the last 12 months. For example, an individual’s significant involvement in the development of a particular product will need to be declared each year as well as at relevant meetings and may restrict that individual’s participation in some discussions.
- 6.4 The chairperson and members’ declaration of their own interests will identify them with the interests declared, but the interests declared do not need to be quantified. For example, in declaring a grant received by a department for which the individual is responsible, only the company name is required, not the value of the grant.
- 6.5 When the annual declaration includes matters relating to other persons, names are not required, nor do the interests declared need to be quantified. For example, in declaring shareholdings only the company name is required, not the numbers or values of shares held. Family members should be referred to simply as: “immediate family member” and closely connected persons as “other person”. In nearly all circumstances this will protect the anonymity of those whose interests must be declared by the serving committee member, although we

recognise that in very exceptional circumstances it may be possible for that individual to be identified.

- 6.6 The annual declaration made by all chairpersons and members of all the CHM, the Committees and EAGs will be published each year in the Annual Report of the Advisory Bodies.

Declarations at meetings

- 6.7 Chairpersons and members are required to declare relevant interests at meetings, whether or not those interests have previously been declared to MHRA. The type of interest must be declared, that is, whether it is personal or non-personal, specific or non-specific or other.
- 6.8 If an issue arises for discussion and an individual is concerned about a matter that could be regarded as affecting his or her impartiality and this matter has not already been declared, he or she must raise this with the MHRA secretariat in advance of the meeting if possible. This will enable the secretariat, wherever possible, to ensure that he or she is not sent any papers concerning issues on which the individual cannot be regarded as impartial. Where it has not been possible to identify such issues in advance, the individual must raise the issue with the MHRA secretariat or the chairperson as early as possible before the meeting takes place, and in any event before discussion of the relevant agenda item. The chairperson of the committee is responsible for taking the decision on how declared interests should be handled.

PARTICIPATION IN DISCUSSIONS WHEN AN INTEREST HAS BEEN DECLARED

- 7.1 "Taking part in discussions" means speaking at meetings or voting. Where an individual is not to take part in a discussion, he or she should leave the room before the discussion commences and return only when that agenda item is complete.
- 7.2 The following paragraphs describe, for each category of interests declared, the actions to be taken.

Personal Interests

- 7.3 A personal specific interest will have been declared if an individual has worked on the product under consideration and is receiving or has received payment for that work. As a general rule, the individual will normally not be allowed to take part in discussions as they relate to that product, except where the chairperson exercises his discretion (which will be rarely exercised) to answer questions from other members. A significant involvement in the development of a product will usually debar an individual from ever participating in discussion on that product. A less significant involvement, or less specific work with or on a product, may not permanently debar an individual, but such decisions will need to be taken on a case by case basis, taking account of the nature of the involvement, its specificity and when the work was undertaken.
- 7.4 If an individual has declared a personal non-specific interest the individual must take no part in discussions on that agenda item, except at the chairperson's discretion to answer questions from other members. If the personal non-specific interest relates to shares that have been disposed of, the individual will generally

be permitted to take part in discussions once three months have elapsed from the date of the disposal of them. If the personal non-specific interest relates to other matters, such as a payment received from a pharmaceutical company, the individual will generally be permitted to take part in discussions once 12 months has elapsed from the date of receipt of payment. However, in some cases it will not be appropriate for the individual to take part even though 12 months have elapsed – for example, where he has an ongoing consultancy or other financial relationship with the pharmaceutical company.

- 7.5 If the individual has declared a personal interest in relation to a member of his or her immediate family, he or she should similarly take no part in discussions except at the chairperson's discretion to answer questions from other members. Such interests may range from a family member's major role in the development of a product under consideration to a family member's shareholdings.

Non-Personal Interests

- 7.6 **A non-personal specific interest** will have been declared if the department for which the individual is responsible is currently receiving payment in respect of work done on the product. The individual will generally not be able to take part in proceedings where a department for which he has responsibility has carried out specific work on the product under discussion.
- 7.7 **A non-personal, non-specific interest** will not normally debar an individual from taking part in discussions, unless exceptional circumstances arise in which it is not appropriate for them to do so.
- 7.8 If an individual declares non-personal interests of an immediate family member, this will not generally prevent him or her from taking part in discussions.

Other Interests

- 7.9 If an individual has declared an interest which does not fall within one of the categories described, but which he or she considers could be perceived as affecting his or her impartiality, whether that individual will be permitted to take part in discussions will depend upon the circumstances. In some cases, it will be sufficient for the individual to declare the interest, so that others taking part in the discussion are aware of his or her interests and can view his or her contribution in that light. An example might be where a member owns retail pharmacies and the discussion addresses the classification of a product from prescription to non-prescription status. In other circumstances it may not be appropriate for an individual to take any part in discussions, except at the chairperson's discretion to answer questions from other members. The chairperson and/or the MHRA Secretariat will advise on these matters. The chairperson of the committee is responsible for taking the decision on how declared interests should be handled.

Rival Products

- 7.10 It is important to remember that not only the company whose application is being considered will be affected by the advice that is given by advisory bodies – companies who make competitor products may also be affected.
- 7.11 If a product is being discussed and an individual is aware that he or she has an interest in a company which markets a rival product, the business of which will directly benefit or suffer as a result of the advice that is given, the individual must

declare that interest at the meeting. An example might be where an application for a generic product is being considered and the individual holds an interest in the current brand-leader, or where a new active substance is under consideration that will directly affect the market of another company for a similar product in which an individual has an interest. Whether the individual will be permitted to take part in discussions will depend upon the circumstances and the extent to which the business of the competitor is likely to be affected

- 7.12 There is no requirement to carry out specific research to identify issues such as these – individuals need only to declare interests of which they are aware.

Consideration of Classes of Products

- 7.13 If an advisory body is considering issues relating to a class of products, the issue of interests remains relevant. Individuals must still declare interests in the usual way. Whether they will be permitted to take part in discussions will depend upon the circumstances, including the class of products being considered, the nature of the advice being given.

RECORD OF INTERESTS

- 8.1 A record is kept in the MHRA of:
- names of chairpersons and members who have declared interests on appointment, when an interest first arises or through the annual declaration, and the nature of the interest;
 - names of chairpersons and members who have declared interests at meetings of the CHM, the Committees and EAGs, giving dates, names of relevant products and companies, details of the interest declared and whether the individual took part in the proceedings.

PUBLICATION

- 9.1 Interests declared to the MHRA by chairpersons and members of all committees, including EAGs, will be published each year in the Annual Reports of the CHM and the Committees (normally published in July).
- 9.2 Interests of immediate family and other closely connected people declared by chairpersons and members will be included in the Annual Reports. This information will provide only the name of the committee chairperson or member, the source of the interest (e.g. the company name), will not provide any financial information nor numbers (e.g. for shares) nor identify the family member or other holding the interest by name.

ADVISORY BOARD ON THE REGISTRATION OF HOMEOPATHIC PRODUCTS: MEMBERS HAVE DECLARED CURRENT PERSONAL AND NON-PERSONAL INTERESTS IN THE PHARMACEUTICAL INDUSTRY AS FOLLOWS:

MEMBER	PERSONAL INTERESTS		NON-PERSONAL INTERESTS		WHETHER CURRENT	ADDITIONAL INFORMATION
	NAME OF COMPANY	NATURE OF INTERESTS	NAME OF COMPANY	NATURE OF INTERESTS		
Professor Angus Mackay	None	None	None	None	No	None
Professor Susan Barker	None	None	None	None	No	Research Scientist for Merck, Sharp and Dohme from 1990 to 1999. Received small pension contribution from that time, managed by their pension provider. Currently works for a university that has some sponsorship for research from various pharmaceutical companies (e.g. Pfizer) and some medical charities
Dr Robert C G Bracchi	None	None	None	None	No	None
Mrs Patricia Donnachie	None	None	None	None	No	None
Ms Susan Hunneyball	None	None	None	None	No	None
Dr Jennifer Lenhart	None	None	None	None	No	None
Professor George B Lockwood	None	None	None	None	No	None
Ms Sarah Mawhinney	None	None	None	None	No	None
Dr Gary J Smyth	None	None	None	None	No	None
Dr Frank Mulder	None	None	None	None	No	None

HERBAL MEDICINES ADVISORY COMMITTEE: MEMBERS HAVE DECLARED CURRENT PERSONAL AND NON-PERSONAL INTERESTS IN THE PHARMACEUTICAL INDUSTRY AS FOLLOWS:

MEMBER	PERSONAL INTERESTS		NON-PERSONAL INTERESTS		WHETHER CURRENT	ADDITIONAL INFORMATION
	NAME OF COMPANY	NATURE OF INTERESTS	NAME OF COMPANY	NATURE OF INTERESTS		
Professor Raymond J Playford	None	None	None	None	No	Director and sole shareholder of Nutritional Bioscience Ltd which is not involved in herbal products or with pharmaceutical companies - Vice President for Research for Pantheryx Inc., a USA company based in Boulder Colorado that produces and distributes bovine colostrum but not herbal or pharmaceutical products.
Dr Paul D Bremner	None	None	None	None	No	Member of the Conservative Party and an elected County (Leicestershire: Division of market Harborough and Foxton) and district (Harborough: ward of Lubenham) Councillor. Has not used this affiliation and membership to influence decisions at HMAC.
Professor Michael Heinrich	None	None	Pukka Herbs, UK	Blockchain systems for QC in herbal products EPSRC - Case Award (student project at the UCL School of Pharmacy)	Yes	Non pharmaceutical sector: CamNutra - collaboration on food substances. Three Spirit - collaboration on functional non-alcoholic drinks. Sibelius - collaboration on supplements
Dr Barbara A Pendry	None	None	None	None	No	None

MEMBER	PERSONAL INTERESTS		NON-PERSONAL INTERESTS			ADDITIONAL INFORMATION
	NAME OF COMPANY	NATURE OF INTERESTS	NAME OF COMPANY	NATURE OF INTERESTS	WHETHER CURRENT	
Dr David Tuthill	Cardiff Paediatrics	Doctor and Director	Diagenics, Mead Johnson, Nutricia, Allergy Therapeutics, Novartis	Organises the South Wales Paediatric Allergy Forum in Cardiff once per year and have this meeting sponsored by a variety of allergy companies into a departmental endowment fund. Receive no personal payment.	Yes	None
Professor Heather M Wallace	None	None	Novabiotics	Shares (less than 0.1% of company)	No	President of EUROTOX. The Society receives sponsorship from many sources for its annual congress. These funds go to the local organising committee (for 2019 Helsinki) who run the conference.
			Antoxis	Shares (less than 0.1% of company)		
			CellProTx	Director		
Dr Jidong Wu	None	None	None	None	No	None
Dr Kaicun Zhao	None	None	None	None	No	None
Dr Robert C G Bracchi	None	None	None	None	No	None
Ms Alison M Denham	None	None	None	None	No	None
Dr Shantha B W Godagama	None	None	None	None	No	None
Professor Philip A Routledge	None	None	None	None	No	None
Dr Deborah J Shaw	None	None	None	None	No	None

Contact for information about these reports:

**Expert Committee Support
Medicines & Healthcare products Regulatory Agency
10 South Colonnade
Canary Wharf
London E14 4PU**

**Tel: 020 3080 6000
info@mhra.gov.uk**